Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

Lumos Pharma logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Advanced Chart

Key Stats

Today's Range
$4.34
$4.34
50-Day Range
$4.30
$4.41
52-Week Range
$1.46
$4.58
Volume
N/A
Average Volume
100,335 shs
Market Capitalization
$37.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.63
Consensus Rating
Buy

Company Overview

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock News Headlines

Lumos Pharma Completes Merger and Delisting Process
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Lumos Pharma reports sustained growth in PGHD trials
Lumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trials
See More Headlines

LUMO Stock Analysis - Frequently Asked Questions

Lumos Pharma, Inc. (NASDAQ:LUMO) issued its earnings results on Thursday, November, 7th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.34. The company earned $0.73 million during the quarter, compared to analyst estimates of $0.50 million. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE).

Company Calendar

Last Earnings
11/07/2024
Today
7/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LUMO
CIK
1126234
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$4.25
Potential Upside/Downside
+98.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.03 million
Net Margins
-1,583.49%
Pretax Margin
-1,583.49%
Return on Equity
-233.03%
Return on Assets
-129.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.66
Quick Ratio
2.66

Sales & Book Value

Annual Sales
$2.21 million
Price / Sales
17.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.45 per share
Price / Book
1.26

Miscellaneous

Outstanding Shares
8,649,000
Free Float
6,452,000
Market Cap
$37.54 million
Optionable
Not Optionable
Beta
0.74
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:LUMO) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners